0001127602-23-003986.txt : 20230208 0001127602-23-003986.hdr.sgml : 20230208 20230208160338 ACCESSION NUMBER: 0001127602-23-003986 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230206 FILED AS OF DATE: 20230208 DATE AS OF CHANGE: 20230208 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Halpin Michael CENTRAL INDEX KEY: 0001778858 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35280 FILM NUMBER: 23599040 MAIL ADDRESS: STREET 1: C/O VERICEL CORPORATION STREET 2: 64 SIDNEY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vericel Corp CENTRAL INDEX KEY: 0000887359 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943096597 STATE OF INCORPORATION: MI FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 64 SIDNEY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 7349305555 MAIL ADDRESS: STREET 1: 64 SIDNEY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: AASTROM BIOSCIENCES INC DATE OF NAME CHANGE: 19960428 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2023-02-06 0000887359 Vericel Corp VCEL 0001778858 Halpin Michael C/O VERICEL CORPORATION CAMBRIDGE MA 02139 1 Chief Operating Officer Common Stock 2023-02-06 4 M 0 1875 0 A 12754 D Common Stock 2023-02-06 4 F 0 988 30.60 D 11766 D Restricted Stock Unit 2023-02-06 4 M 0 1875 D Common Stock 1875 0 D The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 6, 2019. These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs. Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation. No expiration date for this type of award. The Fair Market Value of the vested derivative securities is $30.60 per share. /s/ Sean Flynn, as Attorney-in-Fact for Michael Halpin 2023-02-08